Advertisement

Prostate brachytherapy: the impact of smoking on recurrence and overall survival of localized prostate cancer

American Journal of BioMedicine  Volume 1, Issue 2, pages 58-72, December 2013

doi: 10.18081/ajbm/2333-5106-013-12/58-72


Edwin H. Cohen, Justin Robinson, Paul Margolis, Marcia Gaut, Amie Alperson, Mary Feagin

Abstract

Brachytherapy has been shown to be an efficacious and cost-effective treatment among patients with localized prostate cancer. In this study, we examined the effects of smoking on prostate cancer recurrence and mortality in patients undergoing brachytherapy for locally advanced prostate cancer. The study population consisted of 405 patients with an average age of 73.4 years. Smoking history included 88 (21.7%) patients with no history of smoking, 108(26.6%) patients with one to twenty pack-years, and 209 (51.7%) patients with twenty-one or more pack-years. The impact of smoking history on OS relative to nonsmokers was hazards ratio 1.39 (CI: 0.81-2.64; P<0.05). In conclusion, the era of brachytherapy dose and treatment intensification strategies to improve upon prostate cancer outcomes, our study showed that smoking increases the risk of cancer recurrence and mortality. Patients who have smoked a higher number of pack-years are at increased risk of recurrence and mortality compared to those who smoked less.

Keywords: Brachytherapy; Prostate cancer; Smoking; Hazards ratio


Limited Access               HTML                 Full Text-PDF                Feedback


References

1. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477–86. [PubMed]

2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–19. [PubMed]

3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–8. [PubMed]

4. Finne P, Stenman UH, Määttänen L, Mäkinen T, Tammela TL, Martikainen P, Ruutu M,  et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92: 22–6. [Full Article (HTML)]

5. Wu K. Hu FB, Willett WC, Giovannucci E. Dietary patterns and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2006; 15: 167–71. [PubMed]

6. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Serum lipid-lowering drugs and prostate cancer risk—a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226–32. [PubMed]

7. Whitaker M, Hruby G, Lovett A, Patanjali N. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol. 2011;101(3):490-4. [PubMed]

8. Egawa S, Shimura S, Irie A, et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001;31:541–547. [PubMed]

9. Ishiyama H, Kitano M, Satoh T, et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009;75:23–28. [PubMed]

10. Whitaker M, Hruby G, Lovett A, et al. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 2011;101:490–494. [PubMed]

11. Tiong A, Bydder S, Ebert M, et al. A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys 2010;76:1066–1072. [PubMed]

12. Herrmann MK, Kertesz T, Gsänger T, et al. Gold marker displacement due to needle insertion during HDR brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study. Radiat Oncol 2012;7:24. [PubMed]

13. Tejwani A, Bieniek E, Puckett L, et al. Case series analysis of post-brachytherapy prostate edema and its relevance to post-implant dosimetry. Post-implant prostate edema and dosimetry. J Contemp Brachytherapy 2012;4:75–80. [PubMed]

14. Kolkman-Deurloo IK, Roos MA, Aluwini S. HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation. Radiother Oncol 2011;98:192–197. [PubMed]

15. Sullivan L, Williams SG, Tai KH, et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009;91:232–236. [PubMed]

16. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence.  Cancer Causes Control  2009; 20(10):1799-1810. [PubMed]

17. Daniell HW. A worse prognosis for smokers with prostate cancer.  J Urol 1995;154(1):153-157. [PubMed]

18. Moreira DM, Antonelli JA, Presti JC Jr,  et al.  Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy. Urology 2010;76(5):1218-1223. [PubMed]

19. Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol 2004;171(6, pt 1):2281-2284. [PubMed]

20. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 2003; 61(2): 365-369. [PubMed]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: